You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
山東新華製藥股份(00719.HK):員工持股計劃未減持公司股份

格隆匯4月22日丨山東新華製藥股份(00719.HK)公吿,山東新華製藥股份有限公司(以下簡稱“公司”)於2021年12月29日在巨潮資訊網披露了《關於第一期員工持股計劃進展情況及減持股份的預披露公吿》,鑑於公司第一期員工持股計劃持有人中含有公司董事、監事和高級管理人員,根據《深圳證券交易所上市公司股東及董事、監事、高級管理人員減持股份實施細則》(以下稱“減持細則”)規定,員工持股計劃通過證券交易所集中競價方式減持股份的,將於公吿披露日起15個交易日後的六個月內進行,且任意連續90個自然日內,減持股份的總數不超過公司總股本的1%;同時,根據減持細則第四條第二款規定,員工持股計劃通過集中競價交易減持公司股份的,解除限售後十二個月內減持數量不超過員工持股計劃持股數量的50%。

員工持股計劃持有的股份4,042,592股,佔目前公司總股本669,627,235股的0.60%。

截止2022年4月20日,前述股份減持計劃減持的期間已經過半,根據《上市公司股東、董監高減持股份的若干規定》證監會公吿【2017】9號)以及《深圳證券交易所上市公司股東及董事、監事、高級管理人員減持股份實施細則》的有關規定,現將具體進展情況公吿如下:截止公吿披露日,員工持股計劃未減持公司股份。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account